Breaking News

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Rhizen Pharma announces shows at AACR showcasing its differentiated scientific stage PARP and DHODH packages Preclinical information on Rhizen’s differentiated PARP inhibitor RP12146, suggests a superior haematological safety profile that the enterprise expects will translate by way of ongoing clinical trials. Preclinical information on Rhizen’s ideal-in-class DHODH inhibitor RP7214, implies that it is energetic across […]